Retatrutide vs Orforglipron vs PlexusDx (2026)

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Retatrutide and orforglipron are the two next-generation GLP-1 candidates that everyone is comparing right now, and the comparison usually misses the most important point: as of April 2026, neither one is FDA-approved for sale in the United States. Retatrutide is Eli Lilly’s once-weekly injectable triple agonist (GLP-1, GIP, and glucagon receptors) still working through Phase 3 trials, with the headline TRIUMPH-4 readout showing roughly 28.7% body-weight reduction at the 12 mg dose over 68 weeks. Orforglipron is Lilly’s once-daily oral non-peptide GLP-1, with a New Drug Application submitted in late 2025 and Phase 3 ATTAIN-1 results in the New England Journal of Medicine showing 12.4% weight loss at 36 mg over 72 weeks. Both are exciting. Neither is something a U.S. clinician can prescribe today. This article explains the pipeline, the realistic timelines, the announced versus unknown pricing, and how PlexusDx’s currently-available compounded Semaglutide Injection, Tirzepatide Injection, and Microdose GLP-1 Protocol compare for someone who needs a GLP-1 option in 2026 rather than 2028. PlexusDx does not sell, prescribe, or recommend retatrutide or orforglipron.

Retatrutide vs orforglipron — what you actually need to know in 2026

Both drugs are Eli Lilly assets, both target the GLP-1 axis, and both are still in the regulatory pipeline. Retatrutide is a once-weekly subcutaneous injection that activates three receptors at once — GLP-1, GIP, and glucagon — producing the largest average weight loss of any obesity drug ever tested in published data (about 28.7% at 12 mg over 68 weeks in TRIUMPH-4, with roughly 58.6% of participants reaching ≥25% weight loss). It still has multiple Phase 3 readouts pending in 2026, FDA submission likely in late 2026 or 2027, and a realistic launch window of 2027–2028. Orforglipron is a once-daily oral pill, structurally a non-peptide small molecule, with no food or water restrictions, producing about 12.4% weight loss at 36 mg over 72 weeks in ATTAIN-1. Lilly has submitted the NDA and a National Priority Voucher is accelerating review, with a Q2 2026 decision possible. Lilly has announced self-pay pricing of $149–$399/month through LillyDirect for orforglipron and $50/month for Medicare. Retatrutide pricing has not been announced. None of this is available to a patient walking into a clinic today.

Why this comparison matters — and where it falls apart

It’s tempting to read “28.7% weight loss” on retatrutide and decide that’s the answer, full stop. Two things complicate that reading. First, TRIUMPH-4 was conducted in a knee-osteoarthritis subpopulation; the broader obesity trial (TRIUMPH-1) has not yet reported, so the 28.7% headline is from a single trial in a specific group rather than a generalizable population estimate. Second, retatrutide carried higher rates of GI side effects and treatment discontinuation (about 12.2–18.2%) than orforglipron (about 5.3–10.3%), and the TRIUMPH-4 readout flagged dysesthesia (abnormal sensations like tingling, burning, or numbness) that was not seen in earlier Phase 2 testing. Lilly stated dysesthesia did not lead to discontinuation in that trial, but more data is needed before a clinician can confidently match patients to the molecule. Orforglipron’s tradeoff is the opposite — lower efficacy than the strongest injectables, but a daily pill with no dosing restrictions and a closer launch date.

How they work — triple agonist vs single-receptor oral

Retatrutide is a peptide that binds three incretin and glucagon-family receptors simultaneously: GLP-1 (appetite suppression and insulin response), GIP (insulin response and adipose handling, the same receptor tirzepatide adds on top of GLP-1), and glucagon (energy expenditure and hepatic fat metabolism). The triple-receptor approach is novel — no FDA-approved obesity drug currently activates the glucagon receptor — which is why long-term safety on retatrutide will need its own evidence base rather than borrowing from the existing GLP-1 class. Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist licensed by Lilly from Chugai Pharmaceutical. Because it’s a small molecule rather than a peptide, it survives oral dosing without the empty-stomach window that Rybelsus (oral semaglutide) requires, and it can be manufactured at scale without the cold-chain and biologic-manufacturing constraints that limit injectable peptide supply.

Weight loss data — what each Phase 3 trial actually showed

In the TRIUMPH-4 Phase 3 trial (December 2025 readout, knee-osteoarthritis population), retatrutide at 12 mg produced approximately 28.7% body-weight reduction over 68 weeks using the efficacy estimand — about 71 lbs of weight loss on average — with 58.6% of participants reaching ≥25% weight loss. The more conservative treatment-regimen estimand (which includes participants regardless of adherence) showed about 23.7% / ~60 lbs. In the ATTAIN-1 Phase 3 obesity trial (NEJM, September 2025), orforglipron at 36 mg produced approximately 12.4% weight loss over 72 weeks using the efficacy estimand (~27.3 lbs), with 36.0% of participants reaching ≥15% weight loss. The treatment-regimen estimand showed about 11.2% / ~25 lbs. These trials are not head-to-head; the populations, durations, and endpoints differ, and the 12 mg retatrutide arm represents the highest dose tested rather than a one-size-fits-all dose.

Side effects, safety signals, and the GLP-1 class warnings

Both molecules sit within the broader GLP-1 receptor agonist class on side-effect profile: nausea, vomiting, diarrhea, constipation, abdominal pain, and headache are the most common adverse events. Pancreatitis, gallbladder disease, and acute kidney injury are documented less common events in the class. The boxed warning on FDA-approved GLP-1 labels for thyroid C-cell tumors, based on rodent studies, applies across the class — including both semaglutide and tirzepatide — and patients with personal or family history of medullary thyroid carcinoma or MEN2 should not take GLP-1 medications. Retatrutide’s higher potency correlated with higher discontinuation rates and the TRIUMPH-4 dysesthesia finding noted above. Orforglipron’s ATTAIN-1 readout reported a small increase in pulse rate, consistent with what’s been observed across the GLP-1 class. Full labeling for both drugs will be determined during FDA review.

Realistic timelines — when can you actually get either one?

Orforglipron is closest to market. Lilly submitted the NDA in late 2025 with a National Priority Voucher fast-tracking review, and Reuters reported in March 2026 that Lilly is on track for a Q2 2026 launch. Even if approval lands on schedule, real-world availability through pharmacies and prescribers typically takes another 30–90 days as supply ramps. Retatrutide is further out. Seven Phase 3 trials are still reading out in 2026 (TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRIUMPH-5, TRIUMPH-MMO, TRIUMPH-OA, and TRIUMPH-Outcomes), and Clarivate currently projects a 2028 commercial launch. For someone whose health is being affected by their weight today, the practical question is whether to wait two to four years on the triple-agonist promise, take a Q2 2026 oral pill if it lands on schedule, or start an effective GLP-1 protocol today.

Where PlexusDx fits — what’s actually available right now

PlexusDx Weight Management Protocols use compounded semaglutide and tirzepatide from licensed U.S. compounding pharmacies, with six protocols across four mechanism classes. The Microdose GLP-1 Protocol is $129/mo flat — the entry option for needle-free, low-dose oral GLP-1 in capsule, troche, lozenge, or sublingual format. Semaglutide Injection is $149/mo across five dose levels (0.25 mg to 2.0 mg weekly), the same active ingredient as Wegovy and Ozempic. Tirzepatide Injection is $249/mo across six dose levels (2.5 mg to 15 mg weekly), the GIP/GLP-1 dual-agonist that anchors the closest currently-available analogue to retatrutide’s mechanism (two of the three receptors retatrutide hits). Semaglutide Oral is $249/mo for daily oral dosing across six dose levels (3 mg to 24 mg). Tirzepatide Oral is $279/mo across seven dose levels (5 mg to 25 mg) — an oral dual-agonist option for patients who want to avoid injections without waiting for orforglipron’s launch. GLP-Squared is $249/mo across six provider-titrated dose pairs of compounded semaglutide plus tirzepatide. All protocols are all-inclusive: async provider consultation, prescription, compounded medication, and shipping. Cash-pay, no membership, all 50 states (five states require a scheduled live consultation). None of these protocols are FDA-approved finished drug products — they are pharmacy-prepared formulations of the same active ingredients used in Wegovy, Ozempic, Mounjaro, and Zepbound.

The genetic variable — why population averages aren’t your answer

Whichever GLP-1 path you eventually take — pipeline drug, FDA-approved branded, or compounded protocol — response varies meaningfully across patients. Variants in GLP1R, FTO, MC4R, TCF7L2, and GIPR are associated with measurably different response patterns to GLP-1 and dual-agonist therapy. The Precision Peptide Genetic Test covers 48 genes and 57 variants across 14 health pathways, with 34 weight-management insights and the GIPR rs1800437 variant flagged as the headline marker for differential GLP-1 response. It’s $298 standalone, or $99 as an add-on after your first month on any PlexusDx protocol. Neither retatrutide trial enrollment nor an orforglipron launch will include a genetic baseline by default — both drugs (like every approved GLP-1) start from a population-average titration schedule. A genetic baseline lets a clinician anchor the dosing conversation to your biology rather than to the average patient in a Phase 3 trial.

Should you wait for retatrutide, take orforglipron when it lands, or start now?

Four-question frame. Question 1: Are you medically stable enough to wait two-plus years for retatrutide’s commercial launch? If your weight is currently driving cardiovascular, metabolic, or joint disease, the cost of waiting is non-trivial. Question 2: Is a daily oral pill the deal-breaker for you, and can you wait for the Q2 2026 orforglipron decision? If yes, plan on a 2026 start with the understanding that pricing tiers ($149–$399/mo) are dose-dependent. In the meantime, Semaglutide Oral at $249/mo or Tirzepatide Oral at $279/mo are oral options available today. Question 3: Do you want the strongest currently-available mechanism — a GIP/GLP-1 dual-agonist — without waiting for the triple-agonist pipeline? Tirzepatide Injection at $249/mo covers two of the three receptors retatrutide hits and has years of post-market clinical experience behind it. Question 4: Do you want a genetic baseline informing your dose before week one? Add the Precision Peptide Genetic Test for $99 after your first month on any PlexusDx protocol. None of this is medical advice — it’s a decision frame you can take to a licensed clinician.

Frequently asked questions

Is retatrutide FDA-approved or available by prescription in 2026?

No. Retatrutide is investigational and currently in Phase 3 trials. It has not been submitted to the FDA, and the realistic commercial launch window is 2027–2028. The only legitimate access right now is through a clinical trial enrollment via ClinicalTrials.gov. PlexusDx does not sell, prescribe, or recommend retatrutide.

Is orforglipron FDA-approved yet?

Not as of April 2026. Lilly submitted the NDA in late 2025, a National Priority Voucher is fast-tracking review, and a Q2 2026 decision is possible. Even on schedule, real-world pharmacy availability typically lags approval by 30–90 days as supply ramps.

Which produces more weight loss — retatrutide or orforglipron?

Published Phase 3 efficacy-estimand data shows retatrutide at 12 mg producing about 28.7% weight loss over 68 weeks (TRIUMPH-4) versus orforglipron at 36 mg producing about 12.4% over 72 weeks (ATTAIN-1). These are not head-to-head trials — the populations and designs differ — and retatrutide carried higher GI side-effect and discontinuation rates. Average weight loss does not predict your individual response.

Can I buy retatrutide or orforglipron online from a compounding pharmacy?

No. Any website selling either drug before FDA approval is selling unregulated, unverified products. Compounded semaglutide and tirzepatide are pharmacy-prepared formulations of FDA-approved active ingredients, which is a different regulatory category than an investigational molecule that has never been approved at all. PlexusDx’s compounded protocols cover semaglutide and tirzepatide only.

Is tirzepatide a reasonable substitute for retatrutide while I wait?

Tirzepatide activates two of the three receptors retatrutide targets (GIP and GLP-1) and has produced 15–22% average weight loss in Phase 3 obesity trials with years of post-market experience. PlexusDx’s Tirzepatide Injection at $249/mo or GLP-Squared at $249/mo are the closest currently-available analogues for that mechanism. Discuss any GLP-1 decision with a licensed clinician.

How does orforglipron differ from Rybelsus?

Both are oral GLP-1 medications, but Rybelsus is a peptide form of semaglutide that requires empty-stomach dosing with limited water, while orforglipron is a non-peptide small molecule with no food or water restrictions. PlexusDx’s Semaglutide Oral at $249/mo is a compounded oral semaglutide option available now.

Do retatrutide and orforglipron carry the same thyroid warning as Wegovy and Zepbound?

The boxed warning for thyroid C-cell tumors on FDA-approved GLP-1 labels is based on rodent studies, and full labeling for retatrutide and orforglipron will be determined during FDA review. Patients with personal or family history of medullary thyroid carcinoma or MEN2 should not take GLP-1 medications. This warning applies to both compounded and FDA-approved semaglutide and tirzepatide.

Retatrutide vs Orforglipron vs PlexusDx (2026): Pipeline GLP-1s, Real-World Options | PlexusDx